Advertisement

Multidrug-resistant Tuberculosis

  • Ivan Bastian
  • Françoise Portaels

Part of the Resurgent and Emerging Infectious Diseases book series (REID, volume 1)

Table of contents

  1. Front Matter
    Pages i-xv
  2. Ivan Bastian, Françoise Portaels
    Pages 1-15
  3. Mario C. Raviglione
    Pages 115-131
  4. Charles A. Peloquin, Barbara Auclair
    Pages 163-174
  5. Michael D. Iseman, Gwen A. Huitt
    Pages 175-190
  6. John Crofton, Armand Van Deun
    Pages 191-203
  7. Richard A. Stapledon, Richard Lumb, Irene S. Lim
    Pages 213-224
  8. David M. Weinstock, Kent A. Sepkowitz
    Pages 225-239
  9. Christopher Dye, Brian G. Williams
    Pages 253-267
  10. Paul E. Farmer, Sonya S. Shin, Jaime Bayona, Jim Y. Kim, Jennifer J. Furin, Joel G. Brenner
    Pages 285-306
  11. Back Matter
    Pages 307-312

About this book

Introduction

Multidrug-resistant tuberculosis: past, present and future Ivan Bastian and Franyoise Portaels Mycobacteriology Unit. Institute of Tropical Medicine. Antwerp. Belgium The Lord hath created medicines out of the earth and he that is wise will not abhor them. Ecclesiasticus 38:4, quoted by Selman Waksman when accepting the 1952 Nobel Prize for Medicine that was awarded for the discovery of the first effective antituberculosis drug. streptomycin. which was derived from the soil bacterium, Streptomyces grisells. 1. HISTORICAL PERSPECTIVE This book has been published at the close of the twentieth century when the medical profession and the general community are increasingly concerned about the threat of multidrug-resistant tuberculosis (MDRTB)[1. 2]. However, at this epoch, it is enlightening to move back from our immediate concerns about MDRTB 'hot spots' in Asia, South America, and the former Soviet Union [3], and to place our current predicament in an historical context. If the results of the global survey of antituberculosis drug resistance conducted by the World Health Organisation (WHO) and the International Union against Tuberculosis and Lung Disease (IUATLD) can be extrapolated, only 2. 2% of TB cases worldwide are due to multi drug­ resistant strains [3]. At the beginning of the 20th century, all TB cases were refractory to all available therapies. Great advances had been made during the 19th century in the understanding of the epidemiology and pathogenesis of TB, and in the diagnosis of the disease (reviewed in references 4-7).

Keywords

antimicrobial pharmacology prevention virus

Editors and affiliations

  • Ivan Bastian
    • 1
  • Françoise Portaels
    • 2
  1. 1.Mycobacterium Reference LaboratoryInstitute of Medical & Veterinary ScienceAdelaideAustralia
  2. 2.Mycobacteriology UnitInstitute of Tropical MedicineAntwerpBelgium

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-011-4084-3
  • Copyright Information Kluwer Academic Publishers 2000
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-94-010-5794-3
  • Online ISBN 978-94-011-4084-3
  • Series Print ISSN 1568-1041
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Consumer Packaged Goods